Delivery Order SPE2DR25D1002-SPE2DR26FGN0A
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $18,496.02 to AmerisourceBergen Drug Corp for Benlysta 200 mg/mL auto-injectors. The contract, issued on September 12, 2025, with an ultimate completion date of October 3, 2025, utilizes firm fixed-price pricing with no set-aside designation. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a $6,973.34 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 200 mg/ml Benlysta auto-injector medication on January 9, 2026, with completion targeted for February 2, 2026. The award was made on a non-set-aside, competitive basis and will be performed at the contractor's facility in Conshohocken, Pennsylvania. This delivery order represents a task order under AmerisourceBergen's parent company Cencora, Inc.'s substantial Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $3,486.67 to AmerisourceBergen Drug Corp for the supply of Benlysta 200 mg/ml auto-injector on January 20, 2026, with an ultimate completion date of February 10, 2026. This non-set-aside, firm fixed-price delivery order was issued under AmerisourceBergen's parent company Cencora, Inc.'s substantial Indefinite Delivery Contract with DLA Troop Support Medical, valued at up to $999.9 million through December 2031. The place of...
- The Defense Logistics Agency awarded a $3,486.67 firm fixed-price delivery order to AmerisourceBergen Drug Corp for BENLYSTA 200 mg/ml auto-injector on January 16, 2026, with an ultimate completion date of February 9, 2026. This competitively awarded, non-set-aside contract will be performed at the company's corporate office location in Conshohocken, Pennsylvania. The award represents a task order under AmerisourceBergen's parent company Cencora, Inc.'s larger Indefinite Delivery Contract with...
- The Defense Logistics Agency awarded a delivery order valued at $6,973.34 to AmerisourceBergen Drug Corp for the supply of Benlysta 200 mg/ml auto-injector on January 15, 2026, with an ultimate completion date of February 6, 2026. This firm fixed-price, competitively awarded delivery order was issued without a set-aside designation and represents a task order under AmerisourceBergen's parent company Cencora, Inc.'s significant Indefinite Delivery Contract with DLA Troop Support Medical, valued...
- The Defense Logistics Agency awarded a $6,973.34 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Benlysta 200 mg/ml auto-injector on January 16, 2026, with completion targeted for February 9, 2026. This is a non-set-aside, competitively awarded contract executed at the company's Conshohocken, Pennsylvania location. AmerisourceBergen Drug Corp operates as a subsidiary of parent company Cencora, Inc. (formerly known as AmerisourceBergen), a major pharmaceutical distributor...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $55,488.06 for Benlysta 200 mg/ml auto-injectors on September 17, 2025, with an ultimate completion date of October 8, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract with...
- The Defense Logistics Agency awarded a $3,486.67 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Benlysta 200 mg/mL auto-injector on January 7, 2026, with completion scheduled for January 29, 2026. This non-competitive delivery order was issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (valued at $999,999,999.00 through December 2026), which serves as the primary vehicle for supplying pharmaceutical products and medical...
- The Defense Logistics Agency awarded a $3,082.67 delivery order to AmerisourceBergen Drug Corp for Benlysta 200 mg/ml auto-injectors, with an ultimate completion date of September 25, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded a delivery order valued at $3,248.66 to AmerisourceBergen Drug Corp for Benlysta 200 mg/ml auto-injector on December 19, 2025, with an ultimate completion date of January 13, 2026. This firm fixed-price, non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, a $999.99 billion prime vehicle running through December 2026. AmerisourceBergen, headquartered...
- SPE2DR25D1002Indefinite Delivery Contract
- SPE2DR25D1002-SPE2DR26FGN0ADelivery Order
The Defense Logistics Agency awarded a delivery order valued at $3,486.67 to AmerSourceBergen Drug Corp for the supply of Benlysta 200 mg/ml auto-injectors. This competitively awarded, firm fixed-price contract was issued on January 20, 2026, with an ultimate completion date of February 10, 2026. The place of performance is AmerSourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a task order execution under a larger Indefinite Delivery Contract (IDC) framework between DLA Troop Support Medical and Cencora, Inc. (AmerSourceBergen's parent company), valued at up to $999,999,999.00 through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs. Benlysta (belimumab) is a biologic immunosuppressant medication used primarily in the treatment of systemic lupus erythematosus and lupus nephritis. The delivery order reflects routine pharmaceutical procurement through DLA's established vendor network to support military treatment facilities and federal healthcare systems. As a non-set-aside award, this contract was competed on a full and open basis, demonstrating AmerSourceBergen's continued capability to meet federal medical supply requirements. The company's extensive portfolio of federal contracts and significant IDC vehicle with DLA underscore its critical role as a primary pharmaceutical distributor supporting Department of Defense healthcare operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.5k | 1/19/26 |